Abstract Group: 5.1. Airway Pharmacology and Treatment
Keyword 1: Asthma - management Keyword 2: Treatments Keyword 3: No keyword

Title: Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma

Prof. Dr Otto Chris 30160 Burghuber otto.burghuber@wienkav.at MD ¹, Dr. Gerhard 30161 Köberl Alexandra.Hammer@takeda.com MD ², Dr. Susanna 30162 Lenk-Feik Alexandra.Hammer@takeda.com MD ³, Dr. Monika 30163 Schantl Alexandra.Hammer@takeda.com MD ⁴, Dr. Peter 30164 Sander peter.sander@takeda.com MD ⁵ and Ms. Alexandra 30190 Hammer Alexandra.Hammer@takeda.com ⁶. ¹ Internal Department, Otto Wagner Hospital, Vienna, Austria, 1140 ; ² Pneumology Practice, Feldkirch, Austria, 6800 ; ³ Pneumology Practice, Baden, Austria, 2500 ; ⁴ Pneumology Practice, Graz, Austria, 8010 ; ⁵ Medical Department, Nycomed Deutschland GmbH, Konstanz, Germany and ⁶ Medical Department, Nycomed Pharma GmbH, Vienna, Austria, 1120.

Body: Aim: To evaluate the efficacy and safety profile of ciclesonide (CIC) in the treatment of persistent allergic or non-allergic asthma in a real-life setting in Austria. Methods: 307 patients suffering from persistent asthma of any severity grade (42% treatment-naive) were enrolled in this non-interventional study (NIS). After prescription of CIC (most frequently 160µg/d) patients were observed for 3 months. At study start 85% were prescribed concomitant medication, primarily short-acting β2-agonists. Efficacy was evaluated by FEV1, Asthma Control Questionnaire (ACQ), Asthma Quality of Life- (AQLQ(S)), asthma symptoms, physical activity limitations and use of rescue medication. Results: Mean FEV1 % predicted increased from 75.1±15.4% to 83.7±14.9%. At the end of the observation period, the percentage of patients with daily symptoms had declined from 33.2% to 3.9%, nighttime symptoms from 21.8% to 5.2%, physical activity limitations from 73.9% to 24.4%, and rescue medication usage from 70.0% to 29.3%. The mean total ACQ score was 2.32 ± 1.14 at baseline and 1.08 ±0.88 at study end. The number of patients with well-controlled asthma (ACQ-score <1) increased considerably from 11.0% to 52.2%. Accordingly, clinically important mean improvements were observed in the total self-assessed AQLQ(S) score. A low incidence of adverse drug reactions (ADR) was observed (4 ADRs in 3/307 patients). Conclusion: This NIS in patients with persistent asthma confirmed the efficacy and safety of CIC in routine clinical care showing improvements in symptom control, lung function, and quality of life. CIC was well tolerated in this heterogeneous patient population.